GlaxoSmithKline (GSK; NYSE: GSK), a major UK pharmaceutical company, has entered into its second licensing agreement with Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) within two months, focusing once again on an antibody-drug conjugate (ADC) product candidate. Hansoh has granted GSK exclusive rights to develop, manufacture, and commercialize its novel ADC product, HS-20093, excluding mainland China, Hong Kong, Macau, and Taiwan.
Under the agreement, Hansoh will receive an upfront payment of USD 185 million and is eligible for up to USD 1.525 billion in milestone payments, in addition to tiered royalties based on net sales upon commercialization. GSK anticipates initiating a Phase I clinical study for HS-20093 outside of China in 2024.
HS-20093 is an innovative ADC that targets B7-H3 and is currently under Phase I and Phase II clinical studies in China for the treatment of lung cancer, sarcoma, head and neck cancer, and other solid tumors.- Fineline.com
